Imagine a giant global encyclopedia for cancer that doctors use to decide how to treat patients, but some pages are written based on a few experts' memories rather than hard data. This project creates a visual 'gap map' that highlights exactly where the evidence is strong and where it is missing. It's like a GPS for medical research that tells scientists exactly where they need to dig deeper to make diagnoses more accurate.
Cancer diagnosis currently relies on expert opinions and non-systematic literature searches, creating a risk of bias and misinformation in global treatment standards.
A living Evidence Gap Map (EGM) tool and a series of Megamaps that visualize the quality and quantity of evidence for all tumour types.
If you are a drug developer dealing with uncertainty in target patient populations — this project developed a living evidence map that identifies pockets of low-level evidence. This allows you to pinpoint specific tumor types where new clinical trials are most needed to fill evidence gaps.
If you are a software provider dealing with outdated diagnostic guidelines — this project developed a systematic evidence synthesis tool. You can integrate these evidence levels into your software to provide doctors with a reliability score for different cancer classifications.
If you are a manufacturer dealing with a lack of standardized diagnostic markers — this project developed a tool to map the evidence base of the WHO Classification of Tumours. This helps you align your product development with the highest research standards and global diagnostic needs.
Based on available project data, there is no mention of a commercial price or licensing cost for the tool.
The project aims to integrate its findings into the 6th edition of the WHO Classification of Tumours, which serves as a global reference tool, suggesting a massive scale of application.
Based on available project data, specific IP or licensing agreements are not disclosed.
The tool is designed as a decision-support tool to optimize healthcare delivery by providing a visual map of evidence for cancer classification.
The project period runs from 2022-07-01 to 2026-06-30, with a goal of integration into the WCT 6th edition.
The consortium is research-heavy, consisting of 9 partners across 6 countries. With 4 universities and 3 research organizations, the focus is clearly on scientific validation. However, the inclusion of 2 industry partners (22% ratio) indicates a strategic intent to move these evidence maps from academic theory into practical clinical or commercial application.
Contact the Centre International de Recherche sur le Cancer in France
Contact us to identify specific evidence gaps in your oncology pipeline using the WCT EVI MAP methodology.
